Tel-Aviv Sourasky Medical Center

tasmc.org.il

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

550

Active

45

Phase 3

36

Total enrollment

110,825

Pipeline matrix

Showing 17 of 17 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ultra Rapid Lispro1
Aspirin1
Fecal Microbial Transplant1
Auto Fecal Microbial Transplant (FMT) via enema1
ixazomib-pomalidomide-dexamethasone1
Rebif 44 MCG Per 0.5 ML Prefilled Syringe1
Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.1
Propranolol1
Saline3
rhDNase I1
Morphine4
Nacl 0.9%1
Transdermal fentanyl patch1
Metoprolol1
Plcacebo1
tDCS1
Everolimus (Afinitor) tablets with endocrine therapy1

Next readouts

  • 2025-05-01
  • 2025-07-01
  • 2025-07-14
  • 2025-09-21
  • 2026-03-01
  • 2026-08-31
  • 2026-09
  • 2026-12-31
  • 2027-02
  • 2027-05

Top conditions

  • Pain11
  • Parkinson Disease10
  • Parkinson's Disease9
  • Obesity8
  • Crohn Disease7
  • Ulcerative Colitis7
  • Healthy7
  • Rheumatoid Arthritis6

Frequently asked questions about Tel-Aviv Sourasky Medical Center

How many clinical trials does Tel-Aviv Sourasky Medical Center have on ClinicalTrials.gov?
Tel-Aviv Sourasky Medical Center is listed as the lead sponsor on 550 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
How many of Tel-Aviv Sourasky Medical Center's trials are in Phase 3?
36 of Tel-Aviv Sourasky Medical Center's trials are in Phase 3, spread across 17 active drug programs.
What therapeutic areas does Tel-Aviv Sourasky Medical Center focus on?
Tel-Aviv Sourasky Medical Center's most-studied conditions on ClinicalTrials.gov are Pain, Parkinson Disease, Parkinson's Disease, Obesity, Crohn Disease.
When are Tel-Aviv Sourasky Medical Center's next clinical trial readouts?
Tel-Aviv Sourasky Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Pre-emptive Intravenous Morphine for Acute Post-craniotomy Pain.”, expected around 2025-05-01.